Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05157230 |
Other study ID # |
2021-KAEK-25 2021/08-21 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
September 1, 2021 |
Est. completion date |
December 25, 2021 |
Study information
Verified date |
January 2022 |
Source |
Bursa Yüksek Ihtisas Education and Research Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Pfizer - BioNTech (BNT162b2) COVID - 19 vaccine is the first vaccine to be approved for
emergency use by FDA. The most commonly reported side effect of the BNT162b2 vaccination is
mild-to-moderate pain at injection site, i.e. deltoid muscle. Injection site pain may be
observed during and after vaccine injection, and severity of pain may vary according to the
type of vaccine, patients age, sex, level of anxiety, needle size, injection site and
technique and patient positioning. Vaccination pain is one of the reasons of vaccine
hesitancy and World Health Organization (WHO) recommended various measures to mitigate pain
at the time of vaccination.
Exercise is one of the suggested methods to relieve the pain and anxiety in various
conditions including vaccination site pain. However, we found no studies addressing injection
site pain after the vaccination and pain associated with BNT162b2 vaccine. Aim of our study
is to evaluate effectiveness of deltoid muscle exercises to relieve injection site pain
observed after BNT162b2 vaccination.
Description:
The study was started at the designated COVID - 19 vaccination department of Bursa Yuksek
Ihtisas research and training hospital Approvals was obtained from Republic of Turkey
Ministry of Health and institutional review board and ethics committee and the study was
conducted in concordance with Declaration of Helsinki.
Volunteers were selected among the healthy persons who admitted to our vaccination department
to have BNT162b2 vaccine. Selection criteria were age being over 18, having no physical
disability to perform the physical exercises given and willingness to participate in the
study and sign an informed consent. People under the age of 18, patients with conditions that
prevent them doing the exercises given and who did not want to participate in the study were
excluded from the study.
Volunteers who accept to participate in the study, were randomized in to exercise vs.
no-exercise groups according to a previously formed online randomization list. All
volunteer's demographic data and vaccination status (first or second dose) were recorded.
Both groups were asked to keep a five - day pain diary using numeric rating scale (NRS) and
to also record any use of analgesics, any hospital admissions, any side effects other than
injection site and arm pain and the time of cessation of pain.